Olema Pharmaceuticals (OLMA) is back in focus after Roche’s Phase 3 breast cancer trial for giredestrant missed its primary endpoint, a setback that coincided with a sharp 41% drop in Olema’s share ...
Zacks.com on MSN
Why Is Masco (MAS) Down 18.3% Since Last Earnings Report?
It has been about a month since the last earnings report for Masco (MAS). Shares have lost about 18.3% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results